Heart Failure Therapeutics Patent Landscape Analysis Report 2026 Edition

Heart Failure Therapeutics Market Size, Growth Trends, and Industry Outlook

Heart failure affects an estimated 64 million people worldwide, and about 6.7 million adults in the United States live with the condition. Ageing, hypertension, diabetes, obesity and improved survival after myocardial infarction expand the prevalent population.

North America leads the market, supported by high diagnosis rates, early adoption of SGLT2 inhibitors and established reimbursement for implantable devices. The United States FDA approval of finerenone for heart failure with LVEF of 40% or higher in 2025 widened the treated HFpEF pool. Asia Pacific grows fastest as China and India broaden access to guideline-directed therapy.

The growth rate sits below the sector norm because the base is large and mature. Generic sacubitril/valsartan and dapagliflozin lower net prices, while new classes offset the erosion: acoramidis (approved in 2024) and vutrisiran (approved for ATTR cardiomyopathy in 2025), tirzepatide for obesity-related HFpEF, and finerenone. Devices add volume, with CardioMEMS pulmonary artery sensors, cardiac resynchronisation systems and HeartMate 3 left ventricular assist devices in routine use.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Heart Failure Therapeutics Patent Filing Trends and Innovation Activity

Heart failure patent filings span pharmaceuticals, medical devices and digital monitoring. Drug filings concentrate on crystalline forms, fixed-dose combinations, new-use claims for HFpEF and cardiorenal conditions, and RNA-based therapies for amyloid disease.

The analysis identifies more than 13,000+ patent families, with filing peaks in 2019 to 2021 after SGLT2 inhibitor outcome trials and again in 2023 to 2024 as incretin, gene therapy and myosin modulator applications grew. Device filings remain steady, led by haemodynamic sensors and left ventricular support pumps.

Rising prevalence and the clinical shift towards combination therapy convert directly into continuation filings, new-use claims and device improvements across the sector.

Scope of the Heart Failure Therapeutics Patent Landscape Analysis Report

The report covers granted patents and published applications related to heart failure drugs, biologics, gene and cell therapies, implantable devices and remote monitoring systems. Coverage spans reduced, mildly reduced and preserved ejection fraction, transthyretin amyloid cardiomyopathy and acute decompensated heart failure.

Patent data are consolidated at family level and mapped to therapy type, mechanism and indication. Assignee names are normalised across subsidiaries and acquired entities, and legal status is reviewed for key jurisdictions.

The report profiles pharmaceutical companies, medical device manufacturers, biotechnology developers, universities and research institutes holding heart failure patent assets.

Global Heart Failure Therapeutics Patent Landscape Analysis

Heart Failure Therapeutics Patent Filing Trend Analysis

Heart failure filings grew at an estimated 6% to 8% annually during 2020 to 2024. Growth followed the DAPA-HF and EMPEROR-Reduced outcome trials, which opened SGLT2 inhibitor combination and formulation claims.

Filings in incretin therapies for HFpEF, ATTR cardiomyopathy silencers and cardiac gene therapy rose faster than the sector average after tirzepatide, vutrisiran and acoramidis data. Established neurohormonal classes show flat to declining new filings as originator patents mature.

Leading Companies and Assignee Analysis in the Heart Failure Therapeutics Patent Landscape

Geographic Analysis of Heart Failure Therapeutics Patent Activity

The report assesses patent activity across major jurisdictions, including:

• United States
• Europe
• China
• Japan
• South Korea
• India
• International and WIPO filings

The United States leads filing volume, supported by a large innovator base and a broad device market. China ranks second, with rapid growth in academic and domestic pharmaceutical filings. Europe follows, anchored by the European Patent Office and strong portfolios from German and Swiss assignees.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Heart Failure Therapeutics Technology Segmentation and Innovation Areas

The technology segmentation covers the following therapy and mechanism areas:

• Neurohormonal modulators including ARNI and MRAs
• SGLT2 inhibitors and metabolic therapies
• Incretin therapies for HFpEF
• Cardiac myosin modulators and soluble guanylate cyclase stimulators
• Implantable monitoring, CRT and mechanical circulatory support

Among these, small molecule drug filings account for the largest share, reflecting the SGLT2, ARNI and MRA families.

Competitive Landscape and Emerging Trends in the Heart Failure Therapeutics Market

Competition combines large pharmaceutical groups holding drug franchises with device manufacturers holding sensor, pacing and pump portfolios. Novartis, AstraZeneca and Boehringer Ingelheim defend franchises through combination and new-indication filings. Medtronic and Abbott build device positions in monitoring and mechanical support.

Companies are focusing on:

• ARNI and angiotensin receptor modulators
• SGLT2 inhibitor combinations
• Non-steroidal mineralocorticoid receptor antagonists
• GLP-1 and dual incretin agonists for HFpEF
• Cardiac myosin activators
• ATTR cardiomyopathy stabilisers and silencers
• Pulmonary artery pressure sensors and LVADs

Emerging innovation themes include obesity-linked HFpEF therapies, fixed-dose SGLT2 and MRA combinations, cardiac gene therapy, siRNA for amyloid cardiomyopathy and artificial intelligence-guided haemodynamic monitoring. Digital titration tools for guideline-directed therapy also attract new filings.

Strategic Insights from the Heart Failure Therapeutics Patent Landscape

The landscape shows large expiring franchises alongside new mechanisms. Generic entry for sacubitril/valsartan and dapagliflozin pushes originators towards combinations and new indications. Smaller developers focus on myosin modulation, gene delivery and amyloid depletion.

Technology segments, assignee portfolios and jurisdictional trends are mapped to commercial opportunity. The report provides actionable intelligence supporting:

• Intellectual property strategy
• R&D prioritisation
• Competitive benchmarking
• Technology scouting
• Licensing evaluation
• Partnership assessment
• Investment analysis
• Market entry planning
• Portfolio expansion strategy

Research Methodology for the Heart Failure Therapeutics Patent Landscape Analysis

Patent data were gathered from the USPTO, EPO, WIPO, CNIPA, JPO and national databases using keyword and classification strategies. Queries combined CPC classes A61K31, A61K38, A61K48, A61P9/04, A61N1/362 and A61M60 with heart failure terminology.

Records were screened for relevance, deduplicated and consolidated at family level. Legal status, priority dates and assignee ownership were verified for the leading portfolios.

The market perspective draws on regulatory filings, company disclosures, clinical trial registries and peer-reviewed literature. Estimates of filing growth and patent counts are rounded approximations.

Related Reports

Heart Failure Market

Heart Failure Epidemiology Forecast

Acute Decompensated Heart Failure (ADHF) Pipeline Analysis Report